Literature DB >> 29932939

Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care.

Danny Hadaya1, Akrivoula Soundia2, Earl Freymiller3, Tristan Grogan4, David Elashoff5, Sotirios Tetradis6, Tara L Aghaloo7.   

Abstract

PURPOSE: Medication-related osteonecrosis of the jaws (MRONJ) is a known complication of antiresorptive medications with surgical and nonsurgical treatment options. The aim of this study was to evaluate the effectiveness of nonsurgical therapy using local wound care on management of MRONJ lesions.
MATERIALS AND METHODS: The authors conducted a retrospective cohort study of patients who presented to the University of California-Los Angeles School of Dentistry Oral and Maxillofacial Surgery Clinic for evaluation and treatment of MRONJ. The primary predictor variable was wound care score; secondary predictors were demographics (age, gender), anatomic location, primary condition, and type and time of antiresorptive treatment. Outcomes assessed were disease resolution and time to disease resolution. Statistical analysis was carried out using the Spearman correlation for continuous and ordinal variables or the χ2 test for categorical variables. Time-to-event statistics and Cox proportional hazards models were calculated; a Kaplan-Meier plot was generated to assess time to healing.
RESULTS: One hundred six patients with 117 MRONJ lesions were treated using local wound care; complete disease resolution was observed 71% of lesions, with an additional 22% of lesions undergoing disease improvement. Wound care score was statistically associated with disease resolution and time to resolution, whereas demographics, anatomic site, condition, and type and time of antiresorptive treatment had no effect on resolution.
CONCLUSION: Local wound care increased the likelihood of MRONJ resolution and decreased the time to disease resolution. This strategy can be used in patients who cannot undergo surgery and should be implemented in all patients with MRONJ lesions who are managed nonsurgically.
Copyright © 2018 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29932939      PMCID: PMC6265090          DOI: 10.1016/j.joms.2018.05.025

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  39 in total

1.  Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience.

Authors:  A M Vandone; M Donadio; M Mozzati; M Ardine; M A Polimeni; S Beatrice; L Ciuffreda; M Scoletta
Journal:  Ann Oncol       Date:  2011-03-22       Impact factor: 32.976

Review 2.  Adverse effects of bisphosphonates: implications for osteoporosis management.

Authors:  Kurt A Kennel; Matthew T Drake
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

3.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Authors:  Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

4.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

5.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

6.  Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis.

Authors:  Saki Hayashida; Sakiko Soutome; Souichi Yanamoto; Shigeyuki Fujita; Takumi Hasegawa; Takahide Komori; Yuka Kojima; Hironori Miyamoto; Yasuyuki Shibuya; Nobuhiro Ueda; Tadaaki Kirita; Hirokazu Nakahara; Mitsuyo Shinohara; Masahiro Umeda
Journal:  J Bone Miner Res       Date:  2017-07-11       Impact factor: 6.741

7.  Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.

Authors:  Rebecca Anne Miksad; Kuan-Chi Lai; Thomas Benton Dodson; Sook-Bin Woo; Nathaniel Simon Treister; Omosalewa Akinyemi; Marian Bihrle; Guy Maytal; Meredith August; G Scott Gazelle; J Shannon Swan
Journal:  Oncologist       Date:  2011-01-06

Review 8.  Denosumab and bisphosphonates: different mechanisms of action and effects.

Authors:  Roland Baron; Serge Ferrari; R Graham G Russell
Journal:  Bone       Date:  2010-12-09       Impact factor: 4.398

9.  Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases.

Authors:  Filippo Graziani; Paolo Vescovi; Giuseppina Campisi; Gianfranco Favia; Mario Gabriele; Giovanni Maria Gaeta; Stefano Gennai; Franco Goia; Mario Miccoli; Franco Peluso; Matteo Scoletta; Luigi Solazzo; Giuseppe Colella
Journal:  J Oral Maxillofac Surg       Date:  2012-08-09       Impact factor: 1.895

10.  Disease Stage and Mode of Therapy Are Important Determinants of Treatment Outcomes for Medication-Related Osteonecrosis of the Jaw.

Authors:  Salvatore L Ruggiero; Nina Kohn
Journal:  J Oral Maxillofac Surg       Date:  2015-12       Impact factor: 1.895

View more
  7 in total

1.  Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ).

Authors:  Ioannis Gkouveris; Danny Hadaya; Akrivoula Soundia; Olga Bezouglaia; Yee Chau; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2019-04-03       Impact factor: 4.398

2.  Retrospective Analysis of Treatment Outcomes of Maxillary Sinusitis Associated with Medication-Related Osteonecrosis of the Jaw.

Authors:  Mitsunobu Otsuru; Saki Hayashida; Kota Morishita; Maho Murata; Sakiko Soutome; Miho Sasaki; Yukinori Takagi; Misa Sumi; Masahiro Umeda
Journal:  Int J Environ Res Public Health       Date:  2022-06-17       Impact factor: 4.614

Review 3.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

4.  Volumetric analysis of MRONJ lesions by semiautomatic segmentation of CBCT images.

Authors:  Matthias Zirk; Johannes Buller; Joachim E Zöller; Carola Heneweer; Norbert Kübler; Max-Philipp Lentzen
Journal:  Oral Maxillofac Surg       Date:  2019-10-31

5.  Antiresorptive-Type and Discontinuation-Timing Affect ONJ Burden.

Authors:  D Hadaya; A Soundia; I Gkouveris; O Bezouglaia; S M Dry; F Q Pirih; T L Aghaloo; S Tetradis
Journal:  J Dent Res       Date:  2021-01-21       Impact factor: 8.924

Review 6.  Macrophage Involvement in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Comprehensive, Short Review.

Authors:  Ioannis Gkouveris; Akrivoula Soundia; Panagiotis Gouveris; Dionysia Zouki; Danny Hadaya; Sotirios Tetradis
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.575

Review 7.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.